This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01126437
First received: May 6, 2010
Last updated: May 20, 2014
Last verified: May 2014
Results First Received: May 20, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double-Blind;   Primary Purpose: Treatment
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium 18 mcg
Drug: tiotropium 1.25 mcg (2 actuations/day)
Drug: tiotropium 2.5 mcg (2 actuations/day)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
This table summarizes study treatment disposition and reasons for discontinuation of study medication. Deaths that caused discontinuation from trial medications are included in AEs. Lost to follow−up indicates status at time of discontinuation of trial medication. Vital status was ascertained for 99.7% of patients.

Reporting Groups
  Description
Tiotropium 2.5 mcg and Placebo

Patients receive one of the active tiotropium arms daily

tiotropium 1.25 mcg (2 actuations/day): soft mist inhaler 2 actuations=2 puffs/day

Tiotropium 5 mcg and Placebo

Patients receive one of the active tiotropium arms daily

tiotropium 2.5 mcg (2 actuations/day): soft mist inhaler (2 actuations=2 puffs/day)

Tiotropium 18 mcg and Placebo

Patients receive one of the active tiotropium arms daily

tiotropium 18 mcg: HandiHaler


Participant Flow:   Overall Study
    Tiotropium 2.5 mcg and Placebo   Tiotropium 5 mcg and Placebo   Tiotropium 18 mcg and Placebo
STARTED   5741   5729   5713 
COMPLETED   4400 [1]   4399 [1]   4400 [1] 
NOT COMPLETED   1341   1330   1313 
Not treated                11                18                19 
Sites with data irregularities/fraud                6                6                7 
Adverse Event                602                606                635 
Lack of Efficacy                65                60                59 
Protocol Violation                64                66                41 
Lost to Follow-up                52                63                55 
Withdrawal by Subject                331                335                319 
Other reason not specified                210                176                178 
[1] See Pre-Assignment Details above for comments.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Treated set (TS): This analysis set included all randomized subjects without data irregularities who were documented to have taken at least one dose of investigational treatment.

Reporting Groups
  Description
Tiotropium 2.5 mcg and Placebo

Patients receive one of the active tiotropium arms daily

tiotropium 1.25 mcg (2 actuations/day): soft mist inhaler 2 actuations=2 puffs/day

Tiotropium 5 mcg and Placebo

Patients receive one of the active tiotropium arms daily

tiotropium 2.5 mcg (2 actuations/day): soft mist inhaler (2 actuations=2 puffs/day)

Tiotropium 18 mcg and Placebo

Patients receive one of the active tiotropium arms daily

tiotropium 18 mcg: HandiHaler

Total Total of all reporting groups

Baseline Measures
   Tiotropium 2.5 mcg and Placebo   Tiotropium 5 mcg and Placebo   Tiotropium 18 mcg and Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 5724   5705   5687   17116 
Age 
[Units: Years]
Mean (Standard Deviation)
 65.1  (9.1)   64.9  (9.1)   65.0  (9.0)   65.0  (9.1) 
Gender 
[Units: Participants]
       
Female   1656   1571   1652   4879 
Male   4068   4134   4035   12237 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to All-Cause Mortality   [ Time Frame: Up to 3 years ]

2.  Primary:   Time to First COPD Exacerbation   [ Time Frame: Up to 3 years ]

3.  Secondary:   Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients)   [ Time Frame: Up to 3 years ]

4.  Secondary:   Number of COPD Exacerbations   [ Time Frame: Up to 3 years ]

5.  Secondary:   Time to First Hospitalization Associated With COPD Exacerbation   [ Time Frame: Up to 3 years ]

6.  Secondary:   Number of Hospitalizations Associated With COPD Exacerbation   [ Time Frame: Up to 3 years ]

7.  Secondary:   Time to First Moderate to Severe COPD Exacerbation   [ Time Frame: Up to 3 years ]

8.  Secondary:   Time to Onset of First Major Adverse Cardiovascular Event (MACE)   [ Time Frame: Up to 3 years ]

9.  Secondary:   Time to Death From Major Adverse Cardiovascular Event (MACE)   [ Time Frame: Up to 3 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Prospectively defined outcome events, serious adverse events, adverse events leading to discontinuation, and investigator-determined drug-related adverse events were required for collection in this trial.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01126437     History of Changes
Other Study ID Numbers: 205.452
2009-015713-51 ( EudraCT Number: EudraCT )
Study First Received: May 6, 2010
Results First Received: May 20, 2014
Last Updated: May 20, 2014